文献速递关节外科创伤骨科

择期全髋关节置换术后短期与长期静脉血栓栓塞预防:疗效与安全性的贝叶斯网络Meta分析

Short versus Long Venous Thromboembolism Prophylaxis Following Elective Total Hip Arthroplasty: A Bayesian Network Meta-Analysis of Efficacy and Safety.
PubMed 文献 · J Arthroplasty · 2025-10-31

该网络Meta分析纳入25项研究(n=28,772),比较全髋关节置换术后短期(10-14天)与延长(28-35天)药物预防方案。延长预防与症状性深静脉血栓和肺栓塞风险降低相关,出血与90天死亡率无差异。网络Meta分析中DOAC长期方案降低症状性DVT效果最有利,DOAC短期方案出血风险最低。

核心结论

  • 延长预防与全髋关节置换术后症状性DVT和PE发生率降低相关。
  • 网络Meta分析中DOAC长期方案降低症状性DVT效果最有利,与DOAC短期方案结果相当,DOAC短期方案出血风险最低。
  • 鉴于促进早期活动的路径不断演变,需要当代试验评估短期与延长预防的净获益。

研究设计与样本

  • 贝叶斯网络Meta分析,纳入截至2025年4月比较全髋关节置换术后短期(10-14天)与延长(28-35天)低分子肝素、直接口服抗凝药(DOACs)和阿司匹林方案的研究。
  • 检索获得1,733条记录,最终纳入25项研究(n=28,772;平均年龄62岁;54.3%为女性)。
  • 结局包括症状性深静脉血栓、肺栓塞、大出血和90天死亡率。

主要发现

  • 短期与延长预防在出血或90天死亡率方面无差异。

关键数值与推荐

  • 短期预防方案定义为10至14天,延长预防方案定义为28至35天。
  • 证据等级为Level II。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要当代试验评估短期与延长预防的净获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pharmacological venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA) lacks consensus regarding optimal duration. We conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of commonly used prophylactic strategies. METHODS: This meta-analysis included studies up to April 2025 comparing short duration (10 to 14 days) and extended-duration (28 to 35 days) regimens of low molecular weight heparin, direct oral anticoagulants (DOACs), and aspirin after THA. Outcomes included symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), major bleeding, and 90-day mortality. The search yielded 1,733 records, of which 25 studies (n = 28,772; mean age 62 years; 54.3% women) were included. RESULTS: Short-duration prophylaxis was associated with higher odds of symptomatic DVT (odds ratio (OR): 1.87 [1.19 to 2.94]; P = 0.006) and PE (1.80 [1.02 to 3.18]; P = 0.043) compared with extended-duration regimens, with no difference in bleeding or 90-day mortality. A sensitivity analysis excluding pre-2000 studies showed that the reduction in symptomatic DVT with extended-duration prophylaxis was less pronounced (OR: 1.79 [1.12 to 2.86]; P = 0.014), and the difference in PE was no longer significant. In the five-arm NMA, DOAC-long had the lowest DVT risk (OR 0.69 [0.42 to 1.14]), while low molecular weight heparin-short (OR: 1.97 [1.18 to 3.32]) and aspirin-long (OR: 1.81 [1.10 to 2.99]) significantly increased it. The DOAC-short had the lowest bleeding risk (OR: 0.71 [0.13 to 6.47]), but with high uncertainty. The PE and mortality differences were not significant. CONCLUSIONS: Extended-duration prophylaxis was associated with reduced rates of symptomatic DVT and PE following THA. In the NMA, DOAC-long demonstrated the most favorable efficacy for reducing symptomatic DVT, with comparable results to DOAC-short, while DOAC-short had the lowest bleeding risk. Given evolving pathways that promote early mobilization, a contemporary trial is warranted to assess the net benefit of short-versus extended-duration prophylaxis. LEVEL OF EVIDENCE: Level II.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Kin Nam RH, Selim A, Gaddoura Z, et al. Short versus Long Venous Thromboembolism Prophylaxis Following Elective Total Hip Arthroplasty: A Bayesian Network Meta-Analysis of Efficacy and Safety. J Arthroplasty. 2025. PMID: 41177191. doi:10.1016/j.arth.2025.10.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。